LUIS SAN MIGUEL: Open Payments
NPI 1982088613 · CHULA VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$560 in 24 payments from 13 companies in 2025. Trend: 2023 $622 · 2024 $610 · 2025 $560
Food & beverage: $560
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 8 | $170 |
| Lilly USA, LLC | 4 | $87 |
| Novo Nordisk Inc | 2 | $52 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| ABBVIE INC. | 1 | $20 |
Products named: TRELEGY ELLIPTA, MOUNJARO, LifeVest, OPSUMIT, JARDIANCE, Rybelsus, Ozempic, BREZTRI.
Industry payments across CA — which companies pay providers there.
